Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Novo Nordisk A/S ADR
(NY:
NVO
)
142.74
-1.75 (-1.21%)
Official Closing Price
Updated: 7:00 PM EDT, Jun 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Novo Nordisk A/S ADR
< Previous
1
2
3
4
5
6
7
8
9
...
49
50
Next >
Novo Nordisk Unusual Options Activity For June 13
June 13, 2024
Via
Benzinga
Weight Loss Drugs: Are They Really Magic?
June 13, 2024
Talking about weight and weight loss with Johann Hari, an Ozempic user and the author of "Magic Pill: The Extraordinary Benefits and Disturbing Risks of the New Weight-Loss Drugs."
Via
The Motley Fool
JPMorgan's $500M Venture Capital Fund Bets Big On Weight-Loss Drugs: 'They're All The Rage'
June 13, 2024
JPMorgan's $500M venture capital fund dives into weight-loss craze, eyeing potential market upheaval in pharmaceuticals.
Via
Benzinga
3 Stocks to Buy as Ozempic Surges in Popularity
June 13, 2024
Ozempic has surged in popularity in recent years, but the best may be to come as innovators look to launch new drugs to meet hot demand.
Via
InvestorPlace
Ozempic Maker Novo Nordisk Closes In On Lego As Denmark's Most Valuable Brand: Report
June 12, 2024
Novo Nordisk is challenging Lego A/S for the title of Denmark's most valuable brand, with its brand value surging 59% to $5.1 billion. This growth is fueled by the global popularity of its weight-loss...
Via
Benzinga
6 Analysts Have This To Say About Novo Nordisk
June 10, 2024
Via
Benzinga
Novo Nordisk's Options Frenzy: What You Need to Know
June 06, 2024
Via
Benzinga
Humans Clamor For Weight Loss Drugs, But The Next Users Could Be... Pets?
June 12, 2024
Could GLP-1 drugs for weight loss in pets be the next big thing? Success of Novo Nordisk and Eli Lilly in human market could pave the way.
Via
Benzinga
7 Trending Stocks With Momentum on Their Side
June 12, 2024
Trending stocks offer an opportunity to ride momentum higher and create quick returns for daring investors.
Via
InvestorPlace
Is Eli Lilly the Best Pharmaceutical Stock for You?
June 12, 2024
Eli Lilly is serving a market that may reach $100 billion.
Via
The Motley Fool
Jim Cramer Sees Eli Lilly As More Than A 'One-Trick Pony' After FDA Advisors Back Its Alzheimer's Drug: 'It's Ultimately Headed To A Trillion Dollar Valuation'
June 11, 2024
Jim Cramer has expressed his confidence in Eli Lilly and Co, citing the company's diverse drug portfolio and the recent endorsement of its Alzheimer's treatment by FDA advisors.
Via
Benzinga
Exposures
Product Safety
Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy?
June 11, 2024
Analysts who follow the start-up drugmaker think its stock has a chance to soar, but that doesn't mean it's right for you.
Via
The Motley Fool
Meet The International Megacaps That 'Match Or Surpass' Magnificent Seven Stocks
June 10, 2024
Five mega companies may offer higher earnings and return potential with lower risk.
Via
Investor's Business Daily
Abbott Snags U.S. Clearance To Enter The Obesity Arena, Rivaling Dexcom
June 10, 2024
The FDA clearance for two new CGMs puts Abbott on track to rival Dexcom's new Stelo device.
Via
Investor's Business Daily
Exposures
Product Safety
The Safety Net Seven: 7 Stocks to Own for Unshakeable Returns
June 10, 2024
Although they’re not necessarily the most exciting ideas, investors should turn to safe stocks to buy to manage the market’s ambiguity.
Via
InvestorPlace
Week Of June 9: What's In Store For The Markets
June 09, 2024
The stock market is very similar to the rest of the economy with winners and losers, but many more losers. Many of today’s high-flyers will be unknown ten years from now.
Via
Talk Markets
Topics
Economy
Exposures
Economy
Structure Therapeutics' Stock Is Soaring on the Promise of Its Wegovy Competitor, but Is It a Buy?
June 09, 2024
Structure Therapeutics has a long way to go before beating Wegovy.
Via
The Motley Fool
Here's Why Demand for Ozempic and Wegovy Could Soar Even Higher
June 08, 2024
Novo Nordisk's stock may not look all that expensive when you're focusing on the long-term potential.
Via
The Motley Fool
Profiting from the Crowd: 3 Stocks Set to Surge on Retail Investor Enthusiasm
June 08, 2024
You can use the wisdom of crowds and their fear and greed motives to profit from these three stocks to buy with plenty of room to run.
Via
InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
June 07, 2024
Via
Benzinga
Over 10,000 Lawsuits In Novo Nordisk's Ozempic Case Assigned to New Judge
June 07, 2024
Judge Karen Marston takes over the high-profile Ozempic litigation involving over 10,000 lawsuits. Here's the latest.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
ETFs Bet High On Weight Loss Drugs, But Industry Observers Question Long-Term Potential
June 07, 2024
New ETFs focusing on weight-loss drugs have launched. However, industry observers caution about their long-term prospects and the concentrated risks associated with these investments.
Via
Benzinga
Topics
ETFs
Ozempic, Wegovy Create Domino Effect As New Products Emerge Across Industries To Capture New Consumer Habits
June 07, 2024
Companies from food and beverage to fitness are adapting to the increased demand for these drugs, hoping to capitalize on shifting consumer habits
Via
Benzinga
The 3 Most Undervalued Pharma Stocks to Buy in June 2024
June 06, 2024
These undervalued pharma stocks to buy are worth a look because even when the economy is struggling, consumers need key medicines.
Via
InvestorPlace
Topics
Economy
Exposures
Economy
Why Quality Investors Should Delve into NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) for Investment Opportunities.
June 06, 2024
Why Quality-Oriented Investors Should Consider NYSE:NVO.
Via
Chartmill
Is Viking Therapeutics Stock a Buy on the Dip?
June 06, 2024
Short-term thinking is creating an intriguing opportunity for investors.
Via
The Motley Fool
Ozempic Just Got Even More Bullish For Novo Nordisk Stock, Yet Again
June 06, 2024
The market for treating chronic kidney disease is nearly within reach.
Via
The Motley Fool
Chinese Generic Ozempic, Wegovy Versions Could Put Novo Nordisk At The Risk Of Stiff Competition In Key Market
June 05, 2024
Via
Benzinga
Biotech Blockbusters: 3 Pharma Stocks to Buy in June for Breakthrough Potential
June 05, 2024
If you have the patience and the ability to take a little risk, consider these three biotech stocks to buy since they can really pay off.
Via
InvestorPlace
British Agency Supports Eli Lilly's Weight Loss Drug Mounjaro, Diverging From Restrictions on Rival Novo Nordisk's Wegovy
June 05, 2024
NICE recommends Eli Lilly's Mounjaro for obesity, omitting time limits applied to Novo Nordisk's Wegovy, opening new avenues for long-term treatment.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
49
50
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.